Dr Wong specializes in T cell mediated skin disorders. The major diseases of interest are cutaneous T-cell lymphoma (CTCL) and psoriasis. Consultation in the diagnosis and management for patients with CTCL and psoriasis are offered at OSU Dermatology. In providing state-of-the-art care for patients at OSU, patients will be informed about appropriate clinical trials for cutaneous lymphoma and moderate-to-severe psoriasis and offered the opportunity to participate. In the treatment of CTCL, Dr Wong is the Co-director of a Multi-disciplinary Cutaneous Lymphoma clinic at the James Cancer Hospital in the OSU Comprehensive Cancer Hospital. The approach is for patients to get coordinated care with Dr Porcu, an oncologist and the Co-director, to provide specialty care of CTCL.
In the research laboratory, Dr. Wong’s basic research is focused on the pathogenesis of CTCL. The long term goals are to:
To that end, his laboratory has identified genes that may serve as novel markers for the diagnosis of Sezary disease, a variant of CTCL. He has pioneered the use of these markers to more precisely diagnose patients with skin diseases that may mimic CTCL. The current efforts are focused on studying the genetic basis for the abnormal expression of these genes. Active areas of research includes studying epigenetic mechanisms of gene expression in T cells, and to identify abnormalities that contribute to deregulated gene expression associated with CTCL. The insights gained from this research would be important in a rational mechanistic approach to the design of treatment strategies for improving the care of patients with CTCL.
Dr. Wong oversees a clinical trials unit that is involved in translational research to advance the understanding and treatment of skin diseases. There is an ongoing protocol to obtain specimens to create a biospecimen bank to store samples from patients with a variety of skin diseases to further research to better understand the pathogenesis of skin disease.
We are also participating in epidemiologic studies to monitor patients on systemic therapies to follow long term safety and efficacy of traditional and new treatments. At different times, there may be therapeutic trials for novel investigational drugs for patients with psoriasis and other skin diseases.
The OSU system evaluates 42,300 visits per year - approximately 844 visits for (PsO 696.1) and 42 visits for (PsA 696.0) and approximately 50 visits for (202) cutaneous lymphoma at the dermatology clinic in Gahanna.